Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21655317 | 1.00 | KDM4C (0.43) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL15818455 | 0.81 | KDM4C (0.43) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL12463825 | 0.81 | SLC6A2 (0.38) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL5172771 | 0.79 | KDM4C (0.44) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL24075123 | 0.79 | USP2 (0.45) | USP2ALPLALPIMEN1KMT2A | |
| SCHEMBL12651544 | 0.79 | USP2 (0.45) | USP2ALPLALPIMEN1KMT2A | |
| SCHEMBL12159553 | 0.79 | USP2 (0.45) | USP2ALPLALPIMEN1KMT2A | |
| SCHEMBL5175333 | 0.77 | KDM4C (0.43) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL8368454 | 0.76 | KDM4C (0.51) | KDM4CUSP2ALPLALPIMEN1 | |
| SCHEMBL660720 | 0.75 | KDM4C (0.47) | KDM4CUSP2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | KDM4C 3346/4885USP2 342/4885ALPL 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.